These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 22831750)

  • 1. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
    Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
    Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
    Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
    Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.
    Smolska-Ciszewska B; Miszczyk L; Białas B; Fijałkowski M; Plewicki G; Gawkowska-Suwińska M; Giglok M; Behrendt K; Nowicka E; Zajusz A; Suwiński R
    Radiat Oncol; 2015 Mar; 10():60. PubMed ID: 25884489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ; Marion C; Fuks Z; Leibel SA
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
    Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
    BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
    Lilleby W; Tafjord G; Raabe NK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
    Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
    Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.